COVID-19 breakthrough infections

COVID-19 in individuals fully-vaccinated

Also Known As:

COVID-19 breakthrough; COVID-19 breakthrough infection; breakthrough COVID-19 infection; breakthrough COVID-19 infections; breakthrough infection COVID-19; breakthrough infections COVID-19

Networked: 70 relevant articles (5 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Infections: 526564
Respiratory Tract Diseases: 6015
- Lung Diseases: 22246
  - Pneumonia: 52735
    - Viral Pneumonia: 577
      - COVID-19: 109434
        COVID-19 breakthrough infections: 70
- Respiratory Tract Infections: 14082
  - Pneumonia: 52735
    - Viral Pneumonia: 577
      - COVID-19: 109434
        COVID-19 breakthrough infections: 70
Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Disease Attributes: 18
    - Breakthrough Infections: 1177
      - COVID-19 breakthrough infections: 70

Related Diseases

1.	COVID-19
2.	Infections
3.	Neoplasms (Cancer)
4.	Flank Pain
5.	Disease Progression

Experts

1.	Arjun, R: 2 articles (01/2022 - 12/2021)
2.	Kim, Jae Hyun: 2 articles (01/2022 - 10/2021)
3.	Lee, Junghwan: 2 articles (01/2022 - 10/2021)
4.	Liu, Cong: 2 articles (01/2022 - 10/2021)
5.	Natarajan, Karthik: 2 articles (01/2022 - 10/2021)
6.	Niyas, V K M: 2 articles (01/2022 - 12/2021)
7.	Rogers, James R: 2 articles (01/2022 - 10/2021)
8.	Soroush, Ali: 2 articles (01/2022 - 10/2021)
9.	Ta, Casey: 2 articles (01/2022 - 10/2021)
10.	Weng, Chunhua: 2 articles (01/2022 - 10/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to COVID-19 breakthrough infections:

1.	COVID-19 VaccinesIBA 09/01/2023 - "Our findings revealed variations in the efficacy of different COVID-19 vaccine types against COVID-19 breakthrough infections. " 11/25/2023 - "This study examined the association between the risk of COVID-19 breakthrough infections and receptor binding domain (RBD) antibody levels and receipt of booster of COVID-19 vaccines. " 03/24/2022 - "We conducted a study aiming to evaluate humoral immunity derived from two different COVID-19 vaccines administered to our in-centre HD population and investigated the characteristics of breakthrough COVID-19 infections occurring post-vaccination within this population. " 01/01/2023 - "The incidence and severity of COVID-19 breakthrough infections in the United Arab Emirates (UAE) remain unknown despite extensive COVID-19 vaccine coverage. " 01/01/2022 - "While SARS-CoV-2 vaccines prevent severe disease effectively, postvaccination "breakthrough" COVID-19 infections and transmission among vaccinated individuals remain ongoing concerns. "
2.	VaccinesIBA 11/01/2022 - "Active participants of the Safety and Efficacy of Preventative COVID Vaccines (STOPCoV) study (892 ≥age 70 years and 369 aged 30-50 years) were invited to participate in a sub-study evaluating breakthrough COVID-19 infection. " 11/01/2022 - "COVID-19 breakthrough infections in vaccinated participants of the Safety and Efficacy of Preventative COVID Vaccines sub-study." 11/22/2023 - "We conducted a survey of 2,500 adults in the United States (February 27 - March 9, 2023) in order to better understand the relationship between breakthrough COVID-19 infections and perceived vaccine effectiveness. " 11/22/2023 - "Breakthrough COVID-19 infections and perceived vaccine effectiveness." 11/01/2023 - "SOT recipients mount lower immunological responses to vaccines than general population and are at high risk for breakthrough COVID-19 infections. "
3.	tixagevimabIBA 02/03/2023 - "We aimed at determining the real-world efficacy of tixagevimab and cilgavimab (Evusheld™) in immunosuppressed pwNID in preventing breakthrough COVID-19 infections. " 01/01/2023 - "Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID-19 infections after tixagevimab/cilgavimab, were included. " 08/18/2023 - "Risk factors for breakthrough COVID-19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre-exposure prophylaxis." 02/03/2023 - "In pwNID treated with immunosuppressive therapies, tixagevimab and cilgavimab (Evusheld™) significantly reduced the numbers and severity of breakthrough COVID-19 infections during the Omicron (BA.2-BA.5 variants) wave." 02/03/2023 - "Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study."
4.	cilgavimabIBA 02/03/2023 - "We aimed at determining the real-world efficacy of tixagevimab and cilgavimab (Evusheld™) in immunosuppressed pwNID in preventing breakthrough COVID-19 infections. " 01/01/2023 - "Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID-19 infections after tixagevimab/cilgavimab, were included. " 08/18/2023 - "Risk factors for breakthrough COVID-19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre-exposure prophylaxis." 02/03/2023 - "In pwNID treated with immunosuppressive therapies, tixagevimab and cilgavimab (Evusheld™) significantly reduced the numbers and severity of breakthrough COVID-19 infections during the Omicron (BA.2-BA.5 variants) wave." 02/03/2023 - "Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study."
5.	AntibodiesIBA 11/01/2023 - "Mucosal antibodies play a key role in protection against breakthrough COVID-19 infections and emerging viral variants. " 01/01/2023 - "Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing." 01/01/2023 - "Salivary antibodies delayed initiation following breakthrough COVID-19 infection, especially Omicron BA.2, but rose rapidly thereafter. " 01/01/2022 - "To assess the incidence and risk factors for breakthrough COVID-19 infection in a vaccinated cohort of patients with autoimmune rheumatic diseases (AIRDs) and determine whether antibodies to receptor binding domain of spike protein (anti-RBD) serve as a reliable predictor of susceptibility to such infections. "
6.	Messenger RNA (mRNA)IBA 12/14/2022 - "In this study, human-milk, saliva and blood samples were collected from 33 lactating individuals before and after mRNA-based vaccination and COVID-19 breakthrough infections. " 01/01/2022 - "This study aims to identify risk factors associated with COVID-19 breakthrough infections among fully mRNA-vaccinated individuals. " 01/01/2022 - "Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination." 10/07/2021 - "Question: What risk factors contribute to COVID-19 breakthrough infections among mRNA vaccinated individuals? " 10/01/2021 - "Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida."
7.	Neutralizing AntibodiesIBA 01/01/2023 - "Our study suggests the association of lower neutralizing antibody levels with mortality in ICU patients admitted with COVID-19 breakthrough infections." 09/22/2023 - "Neutralizing Antibody Levels and Epidemiological Characteristics of Patients with Breakthrough COVID-19 Infection in Toyama, Japan." 09/04/2023 - "From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. "
8.	Immunoglobulin A (IgA)IBA 12/01/2023 - "Significance of Anti-COVID-IgA antibody response in COVID-19 breakthrough infection in vaccinated patients - a single-centered study from Pakistan."
9.	BIBP COVID-19 vaccineIBA 12/01/2022 - "In this study, we explored the immunogenicity of COVID-19 breakthrough patients, BBIBP-CorV homologous booster group and BBIBP-CorV/ZF2001 heterologous booster group against SARS-CoV-2 pseudotypes corresponding to the prototype, Beta, Delta, and the emergent Omicron variant.Notably"
10.	ZF2001 COVID-19 vaccineIBA 12/01/2022 - "In this study, we explored the immunogenicity of COVID-19 breakthrough patients, BBIBP-CorV homologous booster group and BBIBP-CorV/ZF2001 heterologous booster group against SARS-CoV-2 pseudotypes corresponding to the prototype, Beta, Delta, and the emergent Omicron variant.Notably"

Therapies and Procedures

1.	Therapeutics 04/28/2022 - "Background: To determine the effect of disease-modifying therapies (DMT) on humoral postvaccine seroconversion, long-term humoral response, and breakthrough COVID-19 infections in persons with multiple sclerosis (PwMS) and other neuroinflammatory disorders. " 01/01/2023 - "Use of anti-CD20 therapies during vaccine breakthrough COVID-19 infection is associated with higher severity. "
2.	Stem Cell Transplantation 08/01/2022 - "Breakthrough Covid-19 infections in vaccinated recipients of allogeneic stem cell transplantation."
3.	Critical Care (Surgical Intensive Care) 01/01/2023 - "The overall clinical effectiveness of tixagevimab/cilgavimab against COVID-19 breakthrough infection, hospitalisation, intensive care admission and COVID-19-specific mortality was 40.54%, 66.19%, 82.13% and 92.39%, respectively. "
4.	Wearable Electronic Devices 01/01/2023 - "Our results suggest commercial-grade wearable technology as a potential platform on which to build screening tools for early detection of illness, including COVID-19 breakthrough cases."